Bank Of Montreal Nuvalent, Inc. Transaction History

Bank Of Montreal

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$62.76 - $81.61 $7.31 Million - $9.5 Million	-116,423 Reduced 59.96%	77,755 $5.9 Million
Q1 2024 May 13, 2024	BUY	$72.35 - $88.99 $7.6 Million - $9.35 Million	105,100 Added 117.99%	194,178 $14.6 Million
Q4 2023 Feb 08, 2024	BUY	$42.42 - $80.28 $3.78 Million - $7.15 Million	89,078 New	89,078 $6.56 Million

210

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $4.02B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.